Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). 2010

Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
Department of Urology, Urology & Nephrology Center, Mansoura University, Mansoura, Egypt.

OBJECTIVE To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO). METHODS A total of 32 male mongrel dogs were classified into 3 groups: sham (8), control (12; left PUO + no medications), and study (12; left PUO + losartan). Dogs of the study and control groups were subjected to 4 weeks of PUO. After that, they were reopened and subjected to Lich-Grigoir ureterovesical reimplantation and then were killed by the end of 32 weeks after relief of obstruction after being evaluated at basal condition; fourth week of obstruction; and at 4, 8, and 32 weeks after relief of obstruction by measurement of selective creatinine clearance (CCr), selective renographic clearance (RC), and renal resistive index. Sham group underwent sham surgery at 4 and 32 weeks and evaluated as the other 2 groups. RESULTS Sham surgery showed no significant effect on any of the evaluated parameters. Compared with the control, losartan saved reduction in CCr by 11% and RC by 20% of the basal value by the end of the fourth week of obstruction, respectively. Moreover, compared with the control, losartan enhanced regain of CCr by 26% and RC by 26% also of the basal value at 32 weeks after relief of fourth week obstruction, respectively. In addition, the increase in renal resistive index was significantly less in the losartan group. CONCLUSIONS Losartan decreases the deterioration of renal function in PUO and enhances recoverability of renal function after relief of obstruction.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014517 Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy. Obstruction, Ureteral,Obstructions, Ureteral,Ureteral Obstructions
D047228 Angiotensin II Type 1 Receptor Blockers Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. Angiotensin II Type 1 Receptor Antagonist,Angiotensin II Type 1 Receptor Blocker,Sartan,Angiotensin 2 Type 1 Receptor Antagonists,Angiotensin II Type 1 Receptor Antagonists,Sartans,Selective Angiotensin II Receptor Antagonists,Type 1 Angiotensin Receptor Antagonists,Type 1 Angiotensin Receptor Blockers
D019808 Losartan An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol,Cozaar,DuP-753,Losartan Monopotassium Salt,Losartan Potassium,MK-954,MK954,DuP 753,DuP753,MK 954,Monopotassium Salt, Losartan,Potassium, Losartan,Salt, Losartan Monopotassium
D020127 Recovery of Function A partial or complete return to the normal or proper physiologic activity of an organ or part following disease or trauma. Function Recoveries,Function Recovery

Related Publications

Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
January 1999, BJU international,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
November 1984, The Journal of urology,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
October 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
June 1974, Kidney international,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
April 2002, Urology,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
January 1979, Transactions of the American Association of Genito-Urinary Surgeons,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
July 1979, Investigative urology,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
April 2013, Academic radiology,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
January 2012, Nephron extra,
Shady A Soliman, and Ahmed A Shokeir, and Ahmed Mosbah, and Hassan Abol-Enein, and Nashwa Barakat, and Essam Abou-Bieh, and Ehab W Wafa
December 2004, American journal of physiology. Renal physiology,
Copied contents to your clipboard!